Georgina V. Long, MD, PhD, on Resected Melanoma: Biomarkers for and Efficacy of Adjuvant Nivolumab vs Placebo
2023 ASCO Annual Meeting
Georgina V. Long, MD, PhD, of Melanoma Institute Australia and The University of Sydney, discusses new data showing that patients with resected stage IIB/C melanoma who were treated with adjuvant nivolumab had prolonged recurrence-free survival compared with placebo across all biomarker subgroups. The baseline biomarkers most predictive of prolonged recurrence-free survival with nivolumab were high interferon gamma score, high tumor mutational burden, CD8 T-cell infiltration, and low C-reactive protein (Abstract 9504).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Georgina V. Long:
Resected Stage 2B and 2C melanoma has a very poor prognosis. In fact, at five years, patients with stage 2C melanoma have a 45% risk of recurrence. And for stage 2B melanoma, 35% risk of recurrence. The survival of this group of patients is worse than that of stage 3A melanoma and the survival of stage 2C melanoma is equivalent to the survival of stage 3B melanoma. This is a poor prognostic group. Checkmate 76K explored adjuvant nivolumab versus placebo in resected stage 2B and 2C melanoma in patients who had undergone a wide local excision and a sentinel node biopsy, which was negative.
790 patients were randomized two to one to nivolumab versus placebo. We've already seen the relapse-free survival primary analysis last year, and there was a 58% reduction in the risk of recurrence with adjuvant nivolumab. We are now presenting the exploratory biomarker analysis from this trial. So baseline, primary melanoma tissue, and baseline CRP, serum CRP was correlated with outcome within each arm and versus each arm. And what we found was that for every biomarker subgroup, nivolumab improved the relapse-free survival over placebo.
And this included tumor mutation burden, interferon gamma, PD-L1 expression at baseline, CD8 infiltration at baseline, the CRP. So when we compared the prognostic biomarkers overall in the trial, we found that the two factors that were most important for prognosis, so predicting recurrence in the total trial population, that was the CRP and the stage. However, when we did our multivariate model to look at what was predictive of best outcome with adjuvant nivolumab over placebo, we found that the baseline biomarkers that were predictive or most predictive were the interferon gamma at baseline and the tumor mutation burden.
Our next steps are to make a multifactorial model, which includes both clinical and tissue biomarkers to predict outcome of patients with resected 2B and 2C melanoma treated with adjuvant nivolumab.
Related Videos
The ASCO Post Staff
Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).
The ASCO Post Staff
Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, both of Memorial Sloan Kettering Cancer Center, discuss findings from the INDIGO trial showing that the IDH1/2 inhibitor vorasidenib improves progression-free survival for patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. These data demonstrate the clinical benefit of vorasidenib in this patient population for whom chemotherapy and radiotherapy are being delayed.
The ASCO Post Staff
Tycel J. Phillips, MD, and Swetha Kambhampati, MD, both of City of Hope National Medical Center, discuss new findings showing that the real-world effectiveness and safety of brexucabtagene autoleucel were similar to data from the pivotal ZUMA-2 trial in patients with relapsed or refractory mantle cell lymphoma, regardless of prior BTK inhibition, bendamustine, or autologous stem cell transplantation (Abstract 7507).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative early breast cancer. When added to standard-of-care endocrine therapy, ribociclib improved invasive disease–free survival with a well-tolerated safety profile (Abstract LBA500).
The ASCO Post Staff
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, and Gregory Roloff, MD, of the University of Chicago, discuss data that are the first to demonstrate post–FDA approval efficacy and toxicity rates of brexucabtagene autoleucel in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Although the data may confirm high response rates associated with this agent, they also highlight the need for interventions to reduce associated toxicities (Abstract 7001).